Drug Development

Pharmalot Allison DeAngelis

Pharmalittle: The ‘godfather’ of biotech trying to save Biogen; pharma companies grapple with ADHD drug shortages

Pharmalot Ed Silverman

Major Indian generic drugmaker closes a U.S. facility after years of manufacturing problems

Pharmalot Ed Silverman

‘A blind eye’: NIH fails to ensure clinical trial results are reported, and still funds researchers who don’t file results

Biotech Matthew Herper

Blueprint Medicines drug reduces mastocytosis symptoms in a new study, meeting investor expectations

Pharmalot Ed Silverman

FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street

Pharmalot Ed Silverman

Contract research organization to transfer 4,000 beagles from facility cited for inhumane care

Pharmalot Ed Silverman

‘Eye-opening’: The Covid-19 pandemic accelerated antimicrobial resistance across the U.S.

Biotech Adam Feuerstein

With ‘do-over’ NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition

Biotech Adam Feuerstein

Anebulo Pharma says study supports development of its pill as an antidote for cannabis intoxication

Biotech Ryan Cross — The Boston Globe

Can Biogen’s backup plan for Alzheimer’s succeed?

Pharmalot Ed Silverman

‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after the company

Biotech Adam Feuerstein

A Celldex treatment induces symptom relief in patients with chronic hives

Biotech Matthew Herper

Uniqure’s Huntington’s gene therapy lowers key protein in small trial

First Opinion Arthur L. Caplan

Needed: a clearer explanation of why diversity in clinical trials is important

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

First Opinion Ravi Gupta and Joseph S. Ross

Reformulating drugs helps profits more than patients

Pharmalot Ed Silverman

FDA oversight of pharma manufacturing facilities plunges during the pandemic

Biotech Allison DeAngelis

Third Rock Ventures plots next chapter after raising $1.1 billion fund

Pharmalot Ed Silverman

In a first-of-its-kind deal, major drugmaker licenses antibiotic production for low-income countries

Pharmalot Ed Silverman

Quantity over quality: FDA approved more cancer drugs than EMA, but they may not have always benefited patients

Biotech Jason Mast

In early trial, drug shrinks tumors in majority of children with most common form of brain cancer

Pharmalot Ed Silverman

Up and down the ladder: The latest comings and goings

Pharmalot Ed Silverman

Former Lilly manager files whistleblower lawsuit over manufacturing failures at production plant

Biotech Angus Chen

Promising results reported for new generation of CAR-T immunotherapy for myeloma

Pharmalot Ed Silverman

drug development

Most Read

A treatment for monkeypox was approved under the FDA’s ‘Animal Rule.’ Here’s what that means

Serious liver side effects detour Amgen’s effort to expand use of its KRAS-blocking lung cancer drug

‘No magic bullet’: For drugmakers and the FDA, clinical trials on ultra-rare diseases pose thorny challenges

Coronavirus hasn’t developed resistance to Paxlovid. How long can that last?

Paxlovid’s failure as a preventative measure raises questions, but doctors still back it as a therapeutic

Covid hasn’t given up all its secrets. Here are 6 mysteries experts hope to unravel

Biden once pledged to ‘cure cancer.’ His new approach is far more modest

Scientists are making CAR-T cells more clever. Here’s what the next generation could look like

All Coverage

Pharmalittle: The ‘godfather’ of biotech trying to save Biogen; pharma companies grapple with ADHD drug shortages

Major Indian generic drugmaker closes a U.S. facility after years of manufacturing problems

‘A blind eye’: NIH fails to ensure clinical trial results are reported, and still funds researchers who don’t file results

Blueprint Medicines drug reduces mastocytosis symptoms in a new study, meeting investor expectations

FDA’s decision to review a Biogen ALS drug is met with skepticism and uncertainty on Wall Street

Contract research organization to transfer 4,000 beagles from facility cited for inhumane care

‘Eye-opening’: The Covid-19 pandemic accelerated antimicrobial resistance across the U.S.

With ‘do-over’ NASH results, Intercept will seek approval for first-ever treatment for fatty liver condition

Anebulo Pharma says study supports development of its pill as an antidote for cannabis intoxication

Can Biogen’s backup plan for Alzheimer’s succeed?

‘A slippery slope’: Pfizer sells a contraceptive and donated to political groups that could come after the company

A Celldex treatment induces symptom relief in patients with chronic hives

Uniqure’s Huntington’s gene therapy lowers key protein in small trial

Needed: a clearer explanation of why diversity in clinical trials is important

Up and down the ladder: The latest comings and goings

Reformulating drugs helps profits more than patients

FDA oversight of pharma manufacturing facilities plunges during the pandemic

Third Rock Ventures plots next chapter after raising $1.1 billion fund

In a first-of-its-kind deal, major drugmaker licenses antibiotic production for low-income countries

Quantity over quality: FDA approved more cancer drugs than EMA, but they may not have always benefited patients

In early trial, drug shrinks tumors in majority of children with most common form of brain cancer

Up and down the ladder: The latest comings and goings

Former Lilly manager files whistleblower lawsuit over manufacturing failures at production plant

Promising results reported for new generation of CAR-T immunotherapy for myeloma

Documents show problems at Novartis facility where cancer drug production was halted

You've been selected! STAT+ for less than $2/day

Subscribe to STAT+ for less than $2 per day